Onalespib and Paclitaxel in Treating Patients With Advanced Triple Negative Breast Cancer
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT02474173 |
|
Recruitment Status :
Terminated
(Drug supply issues)
First Posted : June 17, 2015
Last Update Posted : November 4, 2022
|
Sponsor:
National Cancer Institute (NCI)
Information provided by (Responsible Party):
National Cancer Institute (NCI)
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Terminated |
|---|---|
| Actual Primary Completion Date : | October 26, 2022 |
| Actual Study Completion Date : | October 26, 2022 |